TABLE OF CONTENTS
1 INTRODUCTION 61
1.1 OBJECTIVES OF THE STUDY 61
1.2 MARKET DEFINITION 61
1.3 OVERVIEW OF THE EUROPE LIQUID BIOPSY MARKET 61
1.4 LIMITATIONS 63
1.5 MARKETS COVERED 63
2 MARKET SEGMENTATION 67
2.1 MARKETS COVERED 67
2.2 GEOGRAPHICAL SCOPE 68
2.3 YEARS CONSIDERED FOR THE STUDY 69
2.4 CURRENCY AND PRICING 69
2.5 DBMR TRIPOD DATA VALIDATION MODEL 70
2.6 MULTIVARIATE MODELLING 73
2.7 PRODUCT TYPE LIFELINE CURVE 73
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 74
2.9 DBMR MARKET POSITION GRID 75
2.10 MARKET TESTING TYPE COVERAGE GRID 76
2.11 VENDOR SHARE ANALYSIS 77
2.12 SECONDARY SOURCES 78
2.13 ASSUMPTIONS 78
3 EXECUTIVE SUMMARY 79
4 PREMIUM INSIGHTS 82
4.1 PESTEL ANALYSIS 83
4.2 PORTERS FIVE FORCES 84
5 INDUSTRY INSIGHTS: 85
6 EUROPE LIQUID BIOPSY MARKET, REGULATION 86
7 MARKET OVERVIEW 88
7.1 DRIVERS 90
7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE 90
7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY 91
7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS 92
7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS 93
7.2 RESTRAINTS 94
7.2.1 HIGH COST OF LIQUID BIOPSY TESTS 94
7.2.2 LACK OF STANDARDIZED GUIDELINES 95
7.3 OPPORTUNITIES 96
7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING 96
7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY 97
7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES 97
7.4 CHALLENGES 98
7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY 98
7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES 99
8 EUROPE LIQUID BIOPSY MARKET, BY PRODUCT 100
8.1 OVERVIEW 101
8.2 CONSUMABLES & ACCESSORIES 104
8.2.1 TEST KITS 105
8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT 105
8.2.1.2 DNA ISOLATION KIT 105
8.2.1.3 OTHERS 105
8.2.2 COLLECTION TUBES 105
8.2.2.1 50 PIECES 106
8.2.2.2 100 PIECES 106
8.2.3 ASSAYS 106
8.2.3.1 FLEXIBLE REAGENTS 106
8.2.3.2 SCALABLE REAGENTS 106
8.2.3.3 OTHERS 106
8.2.4 CONTROL KIT 106
8.2.5 OTHERS 106
8.3 INSTRUMENTS 106
8.3.1 ANALYZERS 107
8.3.2 SYSTEMS 107
8.3.3 OTHERS 108
8.4 SERVICES & SOFTWARE 108
8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE 109
8.4.2 DPCR ANALYSIS SOFTWARE 109
8.4.3 CASTPCR ANALYSIS SOFTWARE 109
8.4.4 OTHERS 109
9 EUROPE LIQUID BIOPSY MARKET, BY BIOMAKER TYPE 110
9.1 OVERVIEW 111
9.2 CIRCULATING TUMOR CELLS (CTCS) 114
9.3 CIRCULATING CELL-FREE DNA (CFDNA) 115
9.4 CELL-FREE RNA 116
9.5 EXOSOMES 117
9.6 EXTRACELLULAR VESICLES 118
9.7 OTHERS 119
10 EUROPE LIQUID BIOPSY MARKET, BY SAMPLE TYPE 120
10.1 OVERVIEW 121
10.2 BLOOD SAMPLE-BASED 124
10.3 URINE SAMPLE-BASED 125
10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED 126
10.5 OTHERS 127
11 EUROPE LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE 128
11.1 OVERVIEW 129
11.2 MOLECULAR 132
11.2.1 NGS 133
11.2.2 PCR 133
11.2.3 MICROARRAY 133
11.2.4 PROTEOMICS 133
11.2.5 OTHERS 133
11.3 PROTEOMIC 133
11.3.1 NGS 134
11.3.2 PCR 134
11.3.3 MICROARRAY 134
11.3.4 PROTEOMICS 134
11.3.5 OTHERS 134
11.4 HISTOLOGY/IMAGING 135
12 EUROPE LIQUID BIOPSY MARKET, BY APPLICATION TYPE 136
12.1 OVERVIEW 137
12.2 CANCER APPLICATIONS 140
12.2.1 LUNG 141
12.2.2 BREAST 141
12.2.2.1 EARLY BREAST CANCER 141
12.2.2.2 ADVANCED BREAST CANCER 141
12.2.3 COLORECTAL 141
12.2.4 PROSTRATE 142
12.2.5 LIVER 142
12.2.6 OTHERS 142
12.3 NON-CANCER APPLICATIONS 142
12.3.1 PRENATAL DIAGNOSIS 143
12.3.2 PERSONALIZED IMMUNOTHERAPY 143
12.3.3 OTHERS 143
13 EUROPE LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 144
13.1 OVERVIEW 145
13.2 ROUTINE SCREENING 148
13.3 THERAPY SELECTION 149
13.4 TREATMENT MONITORING 149
13.4.1 EARLY-STAGE DISEASE 150
13.4.2 LATE-STAGE/METASTATIC DISEASE 150
13.5 RECURRENCE MONITORING 151
13.6 PATIENT WORK-UP 151
13.7 OTHERS 152
14 EUROPE LIQUID BIOPSY MARKET, BY TECHNOLOGY 153
14.1 OVERVIEW 154
14.2 MULTI-GENE-PARALLEL ANALYSIS 157
14.3 SINGLE GENE ANALYSIS 158
15 EUROPE LIQUID BIOPSY MARKET, BY END USER 159
15.1 OVERVIEW 160
15.2 HOSPITALS 163
15.3 REFERENCE LABORATORIES 163
15.4 DIAGNOSTIC CENTERS 164
15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES 164
15.6 OTHERS 166
16 EUROPE LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL 167
16.1 OVERVIEW 168
16.2 DIRECT TENDER 171
16.3 THIRD PARTY DISTRIBUTOR 171
16.4 OTHERS 172
17 EUROPE LIQUID BIOPSY MARKET, BY REGION 173
17.1 EUROPE 174
17.1.1 GERMANY 188
17.1.2 FRANCE 197
17.1.3 U.K. 206
17.1.4 ITALY 215
17.1.5 SPAIN 223
17.1.6 RUSSIA 231
17.1.7 TURKEY 239
17.1.8 BELGIUM 247
17.1.9 NETHERLANDS 255
17.1.10 SWITZERLAND 263
17.1.11 REST OF EUROPE 271
18 EUROPE LIQUID BIOPSY MARKET, COMPANY LANDSCAPE 272
18.1 COMPANY SHARE ANALYSIS: EUROPE 272
19 COMPANY PROFILE 273
19.1 F. HOFFMANN-LA ROCHE LTD. 273
19.1.1 COMPANY SNAPSHOT 273
19.1.2 REVENUE ANALYSIS 273
19.1.3 COMPANY SHARE ANALYSIS 274
19.1.4 PRODUCT PORTFOLIO 274
19.1.5 RECENT DEVELOPMENTS 274
19.2 GUARDANT HEALTH 275
19.2.1 COMPANY SNAPSHOT 275
19.2.2 REVENUE ANALYSIS 275
19.2.3 COMPANY SHARE ANALYSIS 276
19.2.4 PRODUCT PORTFOLIO 276
19.2.5 RECENT DEVELOPMENTS 276
19.3 THERMO FISHER SCIENTIFIC INC. 277
19.3.1 COMPANY SNAPSHOT 277
19.3.2 REVENUE ANALYSIS 277
19.3.3 COMPANY SHARE ANALYSIS 278
19.3.4 SWOT ANALYSIS 278
19.3.5 PRODUCT PORTFOLIO 279
19.3.6 RECENT DEVELOPMENTS 280
19.4 EXACT SCIENCE CORPORATION 281
19.4.1 COMPANY SNAPSHOT 281
19.4.2 REVENUE ANALYSIS 281
19.4.3 COMPANY SHARE ANALYSIS 282
19.4.4 PRODUCT PORTFOLIO 282
19.4.5 RECENT DEVELOPMENTS 282
19.5 QIAGEN 283
19.5.1 COMPANY SNAPSHOT 283
19.5.2 REVENUE ANALYSIS 283
19.5.3 COMPANY SHARE ANALYSIS 284
19.5.4 PRODUCT PORTFOLIO 284
19.5.5 RECENT DEVELOPMENTS 285
19.6 ANGLE PLC (2022) 286
19.6.1 COMPANY SNAPSHOT 286
19.6.2 REVENUE ANALYSIS 286
19.6.3 PRODUCT PORTFOLIO 287
19.6.4 RECENT DEVELOPMENT 287
19.7 BIOCEPT, INC. 288
19.7.1 COMPANY SNAPSHOT 288
19.7.2 REVENUE ANALYSIS 288
19.7.3 PRODUCT PORTFOLIO 289
19.7.4 RECENT DEVELOPMENT 289
19.8 BIO-RAD LABORATORIES, INC. (2022) 290
19.8.1 COMPANY SNAPSHOT 290
19.8.2 REVENUE ANALYSIS 290
19.8.3 PRODUCT PORTFOLIO 291
19.8.4 RECENT DEVELOPMENTS 291
19.9 EPIC SCIENCES 292
19.9.1 COMPANY SNAPSHOT 292
19.9.2 PRODUCT PORTFOLIO 292
19.9.3 RECENT DEVELOPMENTS 292
19.10 FLUXION BIOSCIENCES INC 293
19.10.1 COMPANY SNAPSHOT 293
19.10.2 PRODUCT PORTFOLIO 293
19.10.3 RECENT DEVELOPMENTS 293
19.11 ILLUMINA, INC. 294
19.11.1 COMPANY SNAPSHOT 294
19.11.2 REVENUE ANALYSIS 294
19.11.3 SWOT ANALYSIS 295
19.11.4 PRODUCT PORTFOLIO 295
19.11.5 RECENT DEVELOPMENT 295
19.12 JOHNSON & JOHNSON PRIVATE LIMITED 297
19.12.1 COMPANY SNAPSHOT 297
19.12.2 REVENUE ANALYSIS 297
19.12.3 SWOT ANALYSIS 298
19.12.4 PRODUCT PORTFOLIO 298
19.12.5 RECENT DEVELOPMENTS 298
19.13 LABORATORY CORPORATION OF AMERICA HOLDINGS 299
19.13.1 COMPANY SNAPSHOT 299
19.13.2 REVENUE ANALYSIS 299
19.13.3 SWOT ANALYSIS 300
19.13.4 PRODUCT PORTFOLIO 300
19.13.5 RECENT DEVELOPMENT 300
19.14 MDXHEALTH 301
19.14.1 COMPANY SNAPSHOT 301
19.14.2 REVENUE ANALYSIS 301
19.14.3 PRODUCT PORTFOLIO 302
19.14.4 RECENT DEVELOPMENTS 302
19.15 MENARINI SILICON BIOSYSTEMS 303
19.15.1 COMPANY SNAPSHOT 303
19.15.2 PRODUCT PORTFOLIO 303
19.15.3 RECENT DEVELOPMENTS 303
19.16 NATERA, INC. 304
19.16.1 COMPANY SNAPSHOT 304
19.16.2 REVENUE ANALYSIS 304
19.16.3 PRODUCT PORTFOLIO 305
19.16.4 RECENT DEVELOPMENTS 305
19.17 NEOGENOMICS LABORATORIES 306
19.17.1 COMPANY SNAPSHOT 306
19.17.2 REVENUE ANALYSIS 306
19.17.3 PRODUCT PORTFOLIO 307
19.17.4 RECENT DEVELOPMENTS 307

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.